Synosis gains five early-stage CNS compounds from Roche
Roche has licensed CNS start-up Synosis Therapeutics rights to five of its neurological compounds for which it had previously discontinued development.
- Specialty Pharmaceuticals
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.